Kaletra Prescribing & Dosing Schedule

Dosage & Administration Drug label Financial assistance Patient education People also ask

Kaletra(lopinavir / ritonavir)

Kaletra 80 MG / 20 MG in 1 mL Oral Solution

NO BOXED WARNING

Dosage & Administration

Tablets: May be taken with or without food, swallowed whole and not chewed, broken, or crushed.

Oral solution: must be taken with food.

KALETRA oral solution is not recommended for use with polyurethane feeding tubes due to potential incompatibility. Feeding tubes composed of silicone or polyvinyl chloride (PVC) can be used.

Adults :

* Total recommended daily dosage is 800/200 mg given once or twice daily.

* KALETRA can be given as once daily or twice daily regimen. See Full Prescribing Information for details.

* KALETRA once daily dosing regimen is not recommended in:
• Adult patients with three or more of the following lopinavir resistance-associated substitutions: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V.
• In combination with carbamazepine, phenobarbital, or phenytoin.
• In combination with efavirenz, nevirapine, or nelfinavir.
• In pregnant women.

Pediatric Patients (14 days and older) :

* KALETRA once daily dosing regimen is not recommended in pediatric patients.

* Twice daily dose is based on body weight or body surface area.

Concomitant Therapy in Adults and Pediatric Patients:

* Dose adjustments of KALETRA may be needed when co-administering with efavirenz, nevirapine, or nelfinavir.

* KALETRA oral solution should not be administered to neonates before a postmenstrual age (first day of the mother’s last menstrual period to birth plus the time elapsed after birth) of 42 weeks and a postnatal age of at least 14 days has been attained

Pregnancy ( 2.5):

* 400/100 mg twice daily in pregnant patients with no documented lopinavir-associated resistance substitutions.

* There are insufficient data to recommend a KALETRA dose for pregnant patients with any documented KALETRA-associated resistance substitutions.

* No dose adjustment of KALETRA is required for patients during the postpartum period.

drug label

Kaletra Prescribing Information

Contact Medical Science Liaison

Report Adverse Event

financial assistance

Kaletra Financial Assistance Options

Copay savings program

Enroll in Patient Savings Program

Rebate Form

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

patient education

Kaletra Patient Education

To share resource; ask patient to:

1.Pull out phone

2.Open camera

3.Scan QR code with camera

4.Tap link

Patient toolkit

Patient Resources

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Kaletra FAQs

How is the dosage of Kaletra?Kaletra is available in 3 dosages, including 100-25 mg Tab, 200-50 mg Tab and 400-100 mg/5ml Sol

What does Kaletra treat?Kaletra treats Acquired Immunodeficiency Syndrome

What is Kaletra made of?Kaletra contains lopinavir / ritonavir which is a Cytochrome P450 3A Inhibitor

How Is Kaletra Administered?Kaletra is administered as a Oral Pill or Oral Liquid

What Are The Kaletra Mechanism Of Action?Kaletra mechanism of action is Breast Cancer Resistance Protein Inhibitors, Cytochrome P450 1A2 Inducers, Cytochrome P450 2B6 Inducers, Cytochrome P450 2C19 Inducers, Cytochrome P450 2C9 Inducers, Cytochrome P450 2D6 Inhibitors, Cytochrome P450 3A Inducers, Cytochrome P450 3A Inhibitors, Cytochrome P450 3A4 Inhibitors, HIV Protease Inhibitors, Organic Anion Transporting Polypeptide 1B1 Inhibitors, P-Glycoprotein Inhibitors or UDP Glucuronosyltransferases Inducers

FAQ Data Source

Dosage & Administration

Dosage & Administration

drug label

Kaletra Prescribing Information

financial assistance

Kaletra Financial Assistance Options

Copay savings program

patient education

Kaletra Patient Education

Patient toolkit

people also ask

Kaletra FAQs